Fulltext present in this item

Thumbnail
Fulltext: 87324.pdf
Format: PDF
Description: publisher's version
Embargo: until further notice
Title: Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.
Author(s): Luin, M. van ; Ende, M.E. van der; Richter, C.; Visser, M. de; Faraj, D.; Ven, A.J.A.M. van der ; Gelinck, L.; Kroon, F.; Wit, F.W.; Schaik, R.H. van; Kuks, P.F.M.; Burger, D.M.
Publication year: 2010
Source: Aids, vol. 24, iss. 8, (2010), pp. 1223-1226
ISSN: 0269-9370
DOI: https://doi.org/10.1097/QAD.0b013e3283389129
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/87324   https://hdl.handle.net/2066/87324

Display more details
Subject: N4i 2: Invasive mycoses and compromised host
N4i 3: Poverty-related infectious diseases
NCEBP 13: Infectious diseases and international health
NCEBP 13: Infectious diseases and international health
Organization: Clinical Pharmacy
Internal Medicine
Journal title:
Aids
Volume: vol. 24
Issue: iss. 8
Page start: p. 1223
Page end: p. 1226
Abstract:
HIV-infected travellers frequently use atovaquone/proguanil as malaria prophylaxis. We compared atovaquone/proguanil pharmacokinetics between healthy volunteers and HIV-infected patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. The geometric mean ratio (95% confidence interval) area under the curve (AUC)0-->t for atovaquone relative to the healthy volunteers was 0.25 (0.16-0.38), 0.26 (0.17-0.41) and 0.54 (0.35-0.83) for patients on efavirenz, lopinavir/ritonavir and atazanavir/ritonavir, respectively. Proguanil plasma concentrations were also significantly lower (38-43%). Physicians should be alert for atovaquone/proguanil prophylaxis failures in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.

This item appears in the following Collection(s)

Browse

Statistics